Medgenics Announces Actions Taken at Annual Meeting of Stockholders
10 September 2011 - 12:00AM
Business Wire
Medgenics, Inc. (NYSE Amex: MDGN and AIM: MEDU, MEDG)
(the "Company"), the developer of a novel technology for the
sustained production and delivery of therapeutic proteins in
patients using their own tissue, announced today the actions taken
at its Annual Meeting of Stockholders held on September 7, 2011 in
New York, New York, USA.
At a duly called meeting, at which a quorum was present in
person or by proxy, the two proposals (as previously announced on
August 30, 2011) were brought before the stockholders and were all
passed by a majority of the votes cast.
The first proposal related to the election of directors. Each
of the current directors of the Company, Dr. Eugene A. Bauer,
Dr. Andrew L. Pearlman, Mr. Joel S. Kanter, Mr. Gary A. Brukardt,
Dr. Stephen D. McMurray, Mr. Isaac Blech and Dr. Alastair
Clemow, was duly re-elected as a director to serve until the
next annual meeting of stockholders and until his respective
successor shall have been duly elected and qualified.
Pursuant to the second proposal, the stockholders ratified
the selection of Kost Forer Gabbay & Kasierer, a member of
Ernst & Young Global, to serve as the Company's independent
registered public accounting firm for the year ended December 31,
2011.
More detail regarding these actions can be found in the
Company's Notice of Annual Meeting posted on the Company's website
(www.medgenics.com). No other business was brought before the
Annual Meeting of the Stockholders.
About Medgenics
Medgenics is developing and commercializing the Biopump, a
proprietary tissue-based platform technology for the sustained
production and delivery of therapeutic proteins using the patient's
own skin biopsy for the treatment of a range of chronic diseases
including anemia, hepatitis C and hemophilia. Medgenics believes
this approach has multiple benefits compared with current
treatments, which include regular and costly injections of
therapeutic proteins.
Medgenics has three long-acting protein therapy products in
development based on this technology:
- EPODURE (now completing a Phase I/II
dose-ranging trial) to produce and deliver erythropoietin for many
months from a single administration, has demonstrated elevation and
stabilization of hemoglobin levels in anemic patients for 6 to more
than 24 months;
- INFRADURE (to commence a Phase I/II
trial in Israel in 2011) to produce a sustained therapeutic dose of
interferon-alpha for use in the treatment of hepatitis C;
- HEMODURE is a sustained Factor VIII
therapy for the prophylactic treatment of hemophilia, now in
development.
Medgenics intends to develop its innovative products and bring
them to market via strategic partnerships with major pharmaceutical
and/or medical device companies. Since October 2009, HEMODURE has
been the focus of cooperation between Medgenics and a major
healthcare company, a market leader in hemophilia.
In addition to treatments for anemia, hepatitis C and
hemophilia, Medgenics plans to develop and/or out-license a
pipeline of future Biopump products targeting the large and rapidly
growing global protein therapy market, which is forecast to reach
$132 billion in 2013. Other potential applications for Biopumps
include multiple sclerosis, arthritis, pediatric growth hormone
deficiency, obesity and diabetes.
Forward-looking Statements
This release contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, Section 21E
of the Securities Exchange Act of 1934 and as that term is defined
in the Private Securities Litigation Reform Act of 1995, which
include all statements other than statements of historical fact,
including (without limitation) those regarding the Company's
financial position, its development and business strategy, its
product candidates and the plans and objectives of management for
future operations. The Company intends that such forward-looking
statements be subject to the safe harbors created by such laws.
Forward-looking statements are sometimes identified by their use of
the terms and phrases such as "estimate," "project," "intend,"
"forecast," "anticipate," "plan," "planning, "expect," "believe,"
"will," "will likely," "should," "could," "would," "may" or the
negative of such terms and other comparable terminology. All such
forward-looking statements are based on current expectations and
are subject to risks and uncertainties. Should any of these risks
or uncertainties materialize, or should any of the Company's
assumptions prove incorrect, actual results may differ materially
from those included within these forward-looking statements.
Accordingly, no undue reliance should be placed on these
forward-looking statements, which speak only as of the date made.
The Company expressly disclaims any obligation or undertaking to
disseminate any updates or revisions to any forward-looking
statements contained herein to reflect any change in the Company's
expectations with regard thereto or any change in events,
conditions or circumstances on which any such statements are based.
As a result of these factors, the events described in the
forward-looking statements contained in this release may not
occur.
Aevi Genomic Medicine (NASDAQ:GNMX)
Historical Stock Chart
From Sep 2024 to Oct 2024
Aevi Genomic Medicine (NASDAQ:GNMX)
Historical Stock Chart
From Oct 2023 to Oct 2024